Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : A retrospective analysis of the EBMT chronic malignancies working party
Scheid, Christof (University of Cologne)
de Wreede, Liesbeth C (DKMS. German Bone Marrow Donor Center)
Van Biezen, A. (Leiden University Medical Center)
Koenecke, C. (Hannover Medical School)
Göhring, G. (Hannover Medical School)
Volin, L. (HUCH Comprehensive Cancer Center)
Maertens, J. (University Hospitals Gasthuisberg (Leuven, Bélgica))
Finke, Juergen (University of Freiburg)
Passweg, J. (University Hospital)
Beelen, Dietrich (University Hospital)
Cornelissen, J. J. (University Medical Center Rotterdam)
Itälä-Remes, Maija (Turku University Hospital (Finlàndia))
Chevallier, P. (CHU de Nantes)
Russell, N. (Nottingham University)
Petersen, E. (University Medical Centre)
Milpied, N. (Hôpital Haut-leveque)
Richard Espiga, C. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Peniket, A. (Churchill Hospital)
Sierra Llopart, Jordi (Institut d'Investigació Biomèdica Sant Pau)
Mufti, G. (GKT School of Medicine (Londres, Regne Unit))
Crawley, C. (Addenbrookes Hospital (Cambridge, Regne Unit))
Veelken, J.H. (Leiden University Hospital)
Ljungman, P. (Karolinska University Hospital and Karolinska Institutet (Suècia))
Cahn, Jean-Yves (Hopital A. Michallon)
Alessandrino, E.P. (Fondazione IRCCS Policlinico San Matteo (Itàlia))
de Witte, Theo (Radboud University-Nijmegen Medical Centre)
Robin, M. (Hôpital Saint-Louis (París, França))
Kröger, N. (University Hospital Eppendorf)
Universitat Autònoma de Barcelona

Date:	2017
Abstract:	The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23. 6 months, low 55. 0 months, intermediate 19. 7 months, high 13. 5 months, very high 7. 8 months (Po0. 001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23. 6 months, low: 24. 8 months, intermediate 10. 6 months, high 7. 9 months, very high 5. 5 months (Po0. 001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Bone marrow transplantation, Vol. 52 Núm. 11 (january 2017) , p. 1519-1525, ISSN 1476-5365

DOI: 10.1038/bmt.2017.171
PMID: 28892084

7 p, 793.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles